Inozyme Pharma, Inc.

Equities

INZY

US45790W1080

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 13:54:44 2024-07-16 EDT			5-day change	1st Jan Change
5.72 ^USD	+4.76%		+23.04%	+32.86%

07-02	Inozyme Pharma Says US FDA Granted Fast Track Designation to INZ-701 to Treat ABCC6 Deficiency	MT
07-02	Inozyme Pharma Gets FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency	DJ

Inozyme Pharma, Inc. Announces the Resignation of Stephen Basso as Senior Vice President, Finance, Effective May 14, 2021

April 21, 2021 at 04:07 pm

On April 19, 2021, Stephen Basso notified Inozyme Pharma, Inc. of his resignation as Senior Vice President, Finance of the Company. The effective date of Mr. Basso's resignation is May 14, 2021. The Company is currently engaged in a search process for a Chief Financial Officer.

Latest news about Inozyme Pharma, Inc.

Inozyme Pharma Says US FDA Granted Fast Track Designation to INZ-701 to Treat ABCC6 Deficiency	07-02	MT
Inozyme Pharma Gets FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency	07-02	DJ
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency	07-02	CI
Wells Fargo Starts Inozyme Pharma With Overweight Rating, $14 Price Target	05-30	MT
Transcript : Inozyme Pharma, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:40 PM	05-15
Inozyme Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Transcript : Inozyme Pharma, Inc. - Special Call	04-08
Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency and ENPP1 Deficiency	04-08	CI
Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency	03-26	CI
Inozyme Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy in Genomics England's Generation Study of Rare Conditions	23-10-10	CI
Inozyme Pharma, Inc. Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency	23-09-26	CI
Inozyme Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Insider Buy: Inozyme Pharma	23-08-04	MT
Sector Update: Health Care Stocks Rising Late Friday	23-07-28	MT
Sector Update: Health Care	23-07-28	MT
Inozyme Pharma Prices $60 Million Share Offering	23-07-28	MT
Sector Update: Health Care Stocks Declining Late Wednesday	23-07-26	MT
Sector Update: Health Care Stocks Falling Wednesday Afternoon	23-07-26	MT
Sector Update: Health Care	23-07-26	MT
Inozyme Pharma Updates INZ-701 Development Plan After Meetings With US, EU Regulators; Shares Drop	23-07-26	MT
Transcript : Inozyme Pharma, Inc. - Special Call	23-07-26
Inozyme Pharma, Inc. Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency	23-07-26	CI
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in Phase 1b Trial of INZ-701	23-06-27	CI

Chart Inozyme Pharma, Inc.

Duration

Period

More charts

Company Profile

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Companyâs lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.46 USD

Average target price

20 USD

Spread / Average Target

+266.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INOZYME PHARMA, INC.	+32.86%	338M
MODERNA, INC.	+24.81%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.20%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.02%	32.4B
ICON PUBLIC LIMITED COMPANY	+21.04%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+48.76%	14.52B
MEDPACE HOLDINGS, INC.	+47.43%	13.74B
BIO-TECHNE CORPORATION	+3.32%	12.17B

Other Biotechnology & Medical Research